Invesaro

Stocks BCRX Earnings

Earnings

Biocryst Pharmaceuticals Inc (BCRX) earnings

Quarterly results of Biocryst Pharmaceuticals Inc as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.

Free, no password. An email when BCRX files with the SEC.

Next earnings date

Biocryst Pharmaceuticals Inc was expected to report around October 13, 2026; nothing is on file with the SEC yet.

Latest quarter: Q2 FY2026

In Q2 FY2026 (ended June 30, 2026) Biocryst Pharmaceuticals Inc reported revenue of $218.3M (+33.6% on the same quarter a year earlier) and net income of $78.4M (+1,441.7% on the same quarter a year earlier).

Diluted earnings per share were $0.30 (+1,400% on the same quarter a year earlier).

Filed with the SEC on August 5, 2026.

Revenue by quarter
Q3 24: $117.1M $117.1M Q3 24Q4 24: $131.5M $131.5M Q4 24Q1 25: $145.5M $145.5M Q1 25Q2 25: $163.4M $163.4M Q2 25Q3 25: $159.4M $159.4M Q3 25Q4 25: $406.6M $406.6M Q4 25Q1 26: $156.4M $156.4M Q1 26Q2 26: $218.3M $218.3M Q2 26
Net income by quarter
Q3 24: -$14M -$14M Q3 24Q4 24: -$26.8M -$26.8M Q4 24Q1 25: $32K $32K Q1 25Q2 25: $5.1M $5.1M Q2 25Q3 25: $12.9M $12.9M Q3 25Q4 25: $245.8M $245.8M Q4 25Q1 26: -$721.8M -$721.8M Q1 26Q2 26: $78.4M $78.4M Q2 26

Quarter by quarter

QuarterEndedRevenuevs year agoNet incomeEPS
Q2 FY2026June 30, 2026$218.3M+33.6%$78.4M$0.30
Q1 FY2026March 31, 2026$156.4M+7.5%-$721.8M-$2.98
Q4 FY2025December 31, 2025$406.6M+209.1%$245.8M-
Q3 FY2025September 30, 2025$159.4M+36.1%$12.9M$0.06
Q2 FY2025June 30, 2025$163.4M-$5.1M$0.02
Q1 FY2025March 31, 2025$145.5M-$32K$0.00
Q4 FY2024December 31, 2024$131.5M--$26.8M-
Q3 FY2024September 30, 2024$117.1M--$14M-$0.07

Fourth quarters are the fiscal year minus the first three, as most companies report no separate Q4 figures.

Results filings

When is Biocryst Pharmaceuticals Inc's next earnings date?

Biocryst Pharmaceuticals Inc was expected to report around October 13, 2026; nothing is on file with the SEC yet.

What were Biocryst Pharmaceuticals Inc's latest quarterly results?

For Q2 FY2026, which ended June 30, 2026, Biocryst Pharmaceuticals Inc reported revenue of $218.3M and net income of $78.4M (+1,441.7% on the same quarter a year earlier). The figures come from its filing with the SEC.

Is Biocryst Pharmaceuticals Inc's revenue growing?

Revenue in Q2 FY2026 was $218.3M, up 33.6% from $163.4M in the same quarter a year earlier.

Get an email when BCRX reports

Follow BCRX and we email you its next results the day they are filed, with the numbers explained.

Free, no password. An email when BCRX files with the SEC.

Source: quarterly figures Biocryst Pharmaceuticals Inc tags in its 10-Q and 10-K filings (SEC EDGAR XBRL). Not investment advice.

Everything about Biocryst Pharmaceuticals Inc